ELOX

Eloxx Pharmaceuticals Inc

12.50

Oct 19 • 3:59 PM ET -0.53 (-4.07%)

12.50

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: PTCT SION TVTX ABEO ARCT KRYS PROK UNCY VRTX FDMT

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	50.50M
Enterprise Value	-11.47M
Income	-
Sales	-
Book/sh	11.50
Cash/sh	15.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Dec 11, 1998

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.09
P/C	0.81
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.74
Current Ratio	3.74
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.58
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	75.85% 61.60%
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	96.93%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	- -

Insider Own	36.63%
Insider Trans	0.00%
Inst Own	42.87%
Inst Trans	21.37%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.53%
SMA50	-23.17%
SMA200	70.73%
Trades

Shs Outstand	4.04M
Shs Float	2.56M
Short Float	2.11%
Short Ratio	1.22
Short Interest	0.05M
52W High	23.40 -46.58%
52W Low	- -
Volatility	13.22% 10.00%
ATR (14)	1.59
RSI (14)	36.81
Beta	-
Rel Volume	0.73
Avg Volume	44.22K
Volume	32,487

Perf Week	-10.01%
Perf Month	-28.37%
Perf Quarter	4.17%
Perf Half Y	933.06%
Perf YTD	1136263.64%
Perf Year	113636262.50%
Perf 3Y	-31.54%
Perf 5Y	-98.08%
Perf 10Y	-99.11%
Recom	1.00
Target Price	38.25
Prev Close	13.03
Price	12.50
Change %	-4.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-26	Initiated	Cantor Fitzgerald	Overweight
Sep-18-26	Initiated	Leerink Partners	Outperform	$32
Jul-20-26	Initiated	Guggenheim	Buy	$43

Today 04:05PM	Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors (PR Newswire)
Sep-11-26 07:30AM	Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome (PR Newswire)
Aug-12-26 06:00AM	Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. It focuses on the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Arlington, MA.

PresidentMr. Sumit Aggarwal M.B.A.

Interim Chief Financial OfficerMr. Daniel E. Geffken M.B.A.

VP & Head of Corporate DevelopmentMr. John Woolford

Chief Medical OfficerDr. Ali Hariri M.D.

VP & Head of Discovery SciencesDr. Roger Clark

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELOX

Eloxx Pharmaceuticals Inc

Upgrade your Finviz experience